MedTrace Logo

Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects With Cognitive Impairment

NCT03780621 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-11-14

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, two arm cross-over study to determine whether a specific combination of Andrographis paniculata and Withania somnifera can be regarded as a safe and effective treatment for cognitive deficits.

Conditions

  • Cognitive Impairment, Mild

Interventions

DIETARY_SUPPLEMENT

Andrographis and Withania

Combination of Andrographis paniculata and Withania somnifera

DIETARY_SUPPLEMENT

Placebo

Visually identical placebo capsule

Sponsors & Collaborators

  • EuroPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Klaus Koch, MD · NeuroCode AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-06-01
Completion
2019-06-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03780621 on ClinicalTrials.gov